Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $103.0 million.

  • Entrada Therapeutics' Cash from Financing Activities rose 172.73% to $8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 97.95%. This contributed to the annual value of $103.0 million for FY2024, which is 389.44% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Cash from Financing Activities is $103.0 million, which was up 389.44% from $21.0 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Cash from Financing Activities ranged from a high of $307.5 million in FY2021 and a low of $479,000 during FY2022.
  • In the last 3 years, Entrada Therapeutics' Cash from Financing Activities had a median value of $21.0 million in 2023 and averaged $41.5 million.
  • Per our database at Business Quant, Entrada Therapeutics' Cash from Financing Activities slumped by 99.84% in 2022 and then surged by 4,291.86% in 2023.
  • Over the past 5 years, Entrada Therapeutics' Cash from Financing Activities (Yearly) stood at $50.1 million in 2020, then surged by 513.83% to $307.5 million in 2021, then crashed by 99.84% to $479,000 in 2022, then skyrocketed by 4,291.86% to $21.0 million in 2023, then surged by 389.44% to $103.0 million in 2024.